Tucson's newest early-stage capital fund, UA Venture Capital Fund LLC, has announced that it's first investments will be in three UA-connected companies: startups Codelucida, Regulonix and Post.Bid.Ship.

As cancer diagnostics and therapeutics become more personalized, pathologists will require more high-quality tissue from biopsies for testing. To address the challenge, this startup is working to bring a next-generation biopsy instrument invented at the UA to the world.

Donna Zhang, Ph.D. and Georg Wondrak, Ph.D., both College of Pharmacy professors, have developed a means of protecting skin and repairing damage from UV radiation.

Over 3 million new cases of skin cancer are diagnosed annually, but we have a natural defense against cancer-causing UV rays: melanin. Now, the UA has licensed two melanin-producing peptides to startup MCR Therapeutics.

In her new position, Rakhi Gibbons now oversees all TLA licensing operations. Learn more about Rakhi and her new role.

Co-founded by UA alumni, the company was recently named to receive a technology development voucher for work on ultra-high purity isotropic graphite. The technology, licensed to Urbix, began as a sponsored project in the College of Optical Sciences.

AZBigMedia reports that Sinfonía HealthCare Corporation's sale of subsidiary and UA startup SinfoníaRx to Tabula Rasa Healthcare, Inc. has been selected as the 2017 Deal of the Year by the Arizona chapter of the Association for Corporate Growth.

UA's own Sudha Ram, PhD, professor of MIS in the Eller College of Management, tackles university student retention rates by analyzing anonymized student smartcard data.

Iluminos Therapeutics has licensed UA-created compounds that have the potential to treat neurodegenerative disease. The inventors hail from the Department of Pharmacology and Toxicology and the ASU-Banner Neurodegenerative Disease Research Center.

UA researchers Drs. Bhaskar Banerjee and Rongguang “Ron” Liang have invented a dual-view probe for medical endoscopy demonstrated to increase polyp detection rates 58 percent to 98 percent. Their startup, Omniscient, is working to bring the technology to the public.